Results 71 to 80 of about 313 (85)
Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability [PDF]
Open Forum Infectious Diseases, 2017 Karen J Shaw
exaly +3 more sources
Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis [PDF]
Open Forum Infectious Diseases, 2017 BACKGROUND: APX001 is a first-in-class intravenous and orally available broad spectrum antifungal inhibitor of Gwt1, a protein involved in glycosylphosphatidylinositol anchor biosynthesis. This study evaluated efficacy of APX001, alone and in combination with fluconazole (FCN), in a mouse model of cryptococcal meningitis.
John R Perfect, Karen J Shaw
exaly +3 more sources
Absorption, Distribution, and Excretion of 14C-APX001 after Single-Dose Administration to Rats and Monkeys [PDF]
Open Forum Infectious Diseases, 2017 BACKGROUND: APX001 is a small-molecule therapeutic agent in clinical development for the treatment of invasive fungal infections (IFI). METHODS: The absorption, distribution and excretion profiles of [(14)C]APX001-derived radioactivity were determined in rats (albino and pigmented) and monkeys.
Karen J Shaw
exaly +3 more sources
First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects [PDF]
Open Forum Infectious Diseases, 2017 Karen J Shaw
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
Case Medical Research, 2019openaire +1 more source